nodes	percent_of_prediction	percent_of_DWPC	metapath
Lomitapide—ABCB1—Sorafenib—thyroid cancer	0.11	0.281	CbGbCtD
Lomitapide—CYP3A4—Vandetanib—thyroid cancer	0.109	0.279	CbGbCtD
Lomitapide—ABCB1—Doxorubicin—thyroid cancer	0.0666	0.17	CbGbCtD
Lomitapide—CYP3A4—Sorafenib—thyroid cancer	0.0658	0.168	CbGbCtD
Lomitapide—CYP3A4—Doxorubicin—thyroid cancer	0.0399	0.102	CbGbCtD
Lomitapide—Blood potassium decreased—Sorafenib—thyroid cancer	0.0127	0.0212	CcSEcCtD
Lomitapide—Antrafenine—PTGS2—thyroid cancer	0.00768	1	CrCbGaD
Lomitapide—Blood bilirubin increased—Vandetanib—thyroid cancer	0.00758	0.0126	CcSEcCtD
Lomitapide—Gastroenteritis—Vandetanib—thyroid cancer	0.00587	0.00976	CcSEcCtD
Lomitapide—Dermatitis bullous—Vandetanib—thyroid cancer	0.00544	0.00905	CcSEcCtD
Lomitapide—Gastrooesophageal reflux disease—Sorafenib—thyroid cancer	0.00535	0.0089	CcSEcCtD
Lomitapide—Drug interaction—Sorafenib—thyroid cancer	0.00521	0.00867	CcSEcCtD
Lomitapide—Blood bilirubin increased—Sorafenib—thyroid cancer	0.00511	0.0085	CcSEcCtD
Lomitapide—Dehydration—Vandetanib—thyroid cancer	0.00484	0.00805	CcSEcCtD
Lomitapide—Rectal tenesmus—Epirubicin—thyroid cancer	0.0048	0.00798	CcSEcCtD
Lomitapide—Dry skin—Vandetanib—thyroid cancer	0.00477	0.00793	CcSEcCtD
Lomitapide—Nasopharyngitis—Vandetanib—thyroid cancer	0.00465	0.00774	CcSEcCtD
Lomitapide—Gastritis—Vandetanib—thyroid cancer	0.0046	0.00766	CcSEcCtD
Lomitapide—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00459	0.00763	CcSEcCtD
Lomitapide—Influenza—Vandetanib—thyroid cancer	0.0045	0.00748	CcSEcCtD
Lomitapide—Rectal tenesmus—Doxorubicin—thyroid cancer	0.00444	0.00738	CcSEcCtD
Lomitapide—Prothrombin level increased—Epirubicin—thyroid cancer	0.00435	0.00724	CcSEcCtD
Lomitapide—Weight decreased—Vandetanib—thyroid cancer	0.00407	0.00677	CcSEcCtD
Lomitapide—Prothrombin level increased—Doxorubicin—thyroid cancer	0.00403	0.0067	CcSEcCtD
Lomitapide—Infestation NOS—Vandetanib—thyroid cancer	0.00401	0.00667	CcSEcCtD
Lomitapide—Infestation—Vandetanib—thyroid cancer	0.00401	0.00667	CcSEcCtD
Lomitapide—Haematuria—Vandetanib—thyroid cancer	0.00382	0.00636	CcSEcCtD
Lomitapide—Proctalgia—Epirubicin—thyroid cancer	0.00381	0.00634	CcSEcCtD
Lomitapide—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00379	0.00631	CcSEcCtD
Lomitapide—Sinusitis—Vandetanib—thyroid cancer	0.00376	0.00626	CcSEcCtD
Lomitapide—Urinary tract disorder—Vandetanib—thyroid cancer	0.00355	0.00591	CcSEcCtD
Lomitapide—Urethral disorder—Vandetanib—thyroid cancer	0.00353	0.00587	CcSEcCtD
Lomitapide—Proctalgia—Doxorubicin—thyroid cancer	0.00352	0.00586	CcSEcCtD
Lomitapide—Pain in extremity—Sorafenib—thyroid cancer	0.00351	0.00584	CcSEcCtD
Lomitapide—Eye disorder—Vandetanib—thyroid cancer	0.00336	0.00559	CcSEcCtD
Lomitapide—Cardiac disorder—Vandetanib—thyroid cancer	0.00334	0.00556	CcSEcCtD
Lomitapide—Anorectal discomfort—Epirubicin—thyroid cancer	0.00327	0.00544	CcSEcCtD
Lomitapide—Dehydration—Sorafenib—thyroid cancer	0.00326	0.00543	CcSEcCtD
Lomitapide—Mediastinal disorder—Vandetanib—thyroid cancer	0.00324	0.0054	CcSEcCtD
Lomitapide—Dry skin—Sorafenib—thyroid cancer	0.00322	0.00535	CcSEcCtD
Lomitapide—Abdominal pain upper—Sorafenib—thyroid cancer	0.0032	0.00533	CcSEcCtD
Lomitapide—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00316	0.00526	CcSEcCtD
Lomitapide—Nasopharyngitis—Sorafenib—thyroid cancer	0.00314	0.00522	CcSEcCtD
Lomitapide—Malnutrition—Vandetanib—thyroid cancer	0.00313	0.00521	CcSEcCtD
Lomitapide—Gastritis—Sorafenib—thyroid cancer	0.00311	0.00517	CcSEcCtD
Lomitapide—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00309	0.00515	CcSEcCtD
Lomitapide—Anorectal discomfort—Doxorubicin—thyroid cancer	0.00302	0.00503	CcSEcCtD
Lomitapide—Muscle spasms—Vandetanib—thyroid cancer	0.00301	0.00501	CcSEcCtD
Lomitapide—Transaminases increased—Epirubicin—thyroid cancer	0.00294	0.00488	CcSEcCtD
Lomitapide—Abdominal discomfort—Sorafenib—thyroid cancer	0.00291	0.00484	CcSEcCtD
Lomitapide—Weight decreased—Sorafenib—thyroid cancer	0.00274	0.00456	CcSEcCtD
Lomitapide—Transaminases increased—Doxorubicin—thyroid cancer	0.00272	0.00452	CcSEcCtD
Lomitapide—Infestation NOS—Sorafenib—thyroid cancer	0.0027	0.0045	CcSEcCtD
Lomitapide—Infestation—Sorafenib—thyroid cancer	0.0027	0.0045	CcSEcCtD
Lomitapide—Chest pain—Vandetanib—thyroid cancer	0.00267	0.00444	CcSEcCtD
Lomitapide—Arthralgia—Vandetanib—thyroid cancer	0.00267	0.00444	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00265	0.00441	CcSEcCtD
Lomitapide—Dry mouth—Vandetanib—thyroid cancer	0.00261	0.00434	CcSEcCtD
Lomitapide—Haematemesis—Epirubicin—thyroid cancer	0.00257	0.00428	CcSEcCtD
Lomitapide—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00256	0.00425	CcSEcCtD
Lomitapide—Infection—Vandetanib—thyroid cancer	0.00254	0.00423	CcSEcCtD
Lomitapide—Hepatomegaly—Epirubicin—thyroid cancer	0.00252	0.0042	CcSEcCtD
Lomitapide—Nervous system disorder—Vandetanib—thyroid cancer	0.00251	0.00417	CcSEcCtD
Lomitapide—Skin disorder—Vandetanib—thyroid cancer	0.00248	0.00413	CcSEcCtD
Lomitapide—Blister—Epirubicin—thyroid cancer	0.00248	0.00412	CcSEcCtD
Lomitapide—Urinary tract disorder—Sorafenib—thyroid cancer	0.0024	0.00399	CcSEcCtD
Lomitapide—Connective tissue disorder—Sorafenib—thyroid cancer	0.00239	0.00397	CcSEcCtD
Lomitapide—Urethral disorder—Sorafenib—thyroid cancer	0.00238	0.00396	CcSEcCtD
Lomitapide—Haematemesis—Doxorubicin—thyroid cancer	0.00238	0.00396	CcSEcCtD
Lomitapide—Hepatomegaly—Doxorubicin—thyroid cancer	0.00234	0.00388	CcSEcCtD
Lomitapide—Rash erythematous—Epirubicin—thyroid cancer	0.00233	0.00388	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00233	0.00387	CcSEcCtD
Lomitapide—Paraesthesia—Vandetanib—thyroid cancer	0.0023	0.00382	CcSEcCtD
Lomitapide—Blister—Doxorubicin—thyroid cancer	0.00229	0.00381	CcSEcCtD
Lomitapide—Cardiac disorder—Sorafenib—thyroid cancer	0.00225	0.00375	CcSEcCtD
Lomitapide—Dyspepsia—Vandetanib—thyroid cancer	0.00225	0.00374	CcSEcCtD
Lomitapide—Decreased appetite—Vandetanib—thyroid cancer	0.00222	0.0037	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00221	0.00367	CcSEcCtD
Lomitapide—Fatigue—Vandetanib—thyroid cancer	0.0022	0.00367	CcSEcCtD
Lomitapide—Mediastinal disorder—Sorafenib—thyroid cancer	0.00219	0.00364	CcSEcCtD
Lomitapide—Constipation—Vandetanib—thyroid cancer	0.00219	0.00364	CcSEcCtD
Lomitapide—Rash erythematous—Doxorubicin—thyroid cancer	0.00216	0.00359	CcSEcCtD
Lomitapide—Malnutrition—Sorafenib—thyroid cancer	0.00211	0.00352	CcSEcCtD
Lomitapide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00209	0.00348	CcSEcCtD
Lomitapide—Muscle spasms—Sorafenib—thyroid cancer	0.00203	0.00338	CcSEcCtD
Lomitapide—Abdominal pain—Vandetanib—thyroid cancer	0.00202	0.00336	CcSEcCtD
Lomitapide—Body temperature increased—Vandetanib—thyroid cancer	0.00202	0.00336	CcSEcCtD
Lomitapide—Anaemia—Sorafenib—thyroid cancer	0.00195	0.00325	CcSEcCtD
Lomitapide—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00189	0.00314	CcSEcCtD
Lomitapide—Asthenia—Vandetanib—thyroid cancer	0.00183	0.00305	CcSEcCtD
Lomitapide—Gait disturbance—Epirubicin—thyroid cancer	0.00183	0.00304	CcSEcCtD
Lomitapide—Arthralgia—Sorafenib—thyroid cancer	0.0018	0.00299	CcSEcCtD
Lomitapide—Myalgia—Sorafenib—thyroid cancer	0.0018	0.00299	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00179	0.00297	CcSEcCtD
Lomitapide—Dry mouth—Sorafenib—thyroid cancer	0.00176	0.00293	CcSEcCtD
Lomitapide—Eructation—Epirubicin—thyroid cancer	0.00176	0.00292	CcSEcCtD
Lomitapide—Diarrhoea—Vandetanib—thyroid cancer	0.00175	0.00291	CcSEcCtD
Lomitapide—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00175	0.00291	CcSEcCtD
Lomitapide—Infection—Sorafenib—thyroid cancer	0.00171	0.00285	CcSEcCtD
Lomitapide—Gait disturbance—Doxorubicin—thyroid cancer	0.00169	0.00282	CcSEcCtD
Lomitapide—Nervous system disorder—Sorafenib—thyroid cancer	0.00169	0.00281	CcSEcCtD
Lomitapide—Dizziness—Vandetanib—thyroid cancer	0.00169	0.00281	CcSEcCtD
Lomitapide—Skin disorder—Sorafenib—thyroid cancer	0.00168	0.00279	CcSEcCtD
Lomitapide—Vomiting—Vandetanib—thyroid cancer	0.00163	0.0027	CcSEcCtD
Lomitapide—Eructation—Doxorubicin—thyroid cancer	0.00162	0.0027	CcSEcCtD
Lomitapide—Ecchymosis—Epirubicin—thyroid cancer	0.00162	0.00269	CcSEcCtD
Lomitapide—Headache—Vandetanib—thyroid cancer	0.0016	0.00266	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00157	0.00261	CcSEcCtD
Lomitapide—Nausea—Vandetanib—thyroid cancer	0.00152	0.00253	CcSEcCtD
Lomitapide—Dyspepsia—Sorafenib—thyroid cancer	0.00152	0.00253	CcSEcCtD
Lomitapide—Decreased appetite—Sorafenib—thyroid cancer	0.0015	0.00249	CcSEcCtD
Lomitapide—Ecchymosis—Doxorubicin—thyroid cancer	0.00149	0.00249	CcSEcCtD
Lomitapide—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00149	0.00248	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00149	0.00248	CcSEcCtD
Lomitapide—Fatigue—Sorafenib—thyroid cancer	0.00149	0.00247	CcSEcCtD
Lomitapide—Constipation—Sorafenib—thyroid cancer	0.00147	0.00245	CcSEcCtD
Lomitapide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00141	0.00235	CcSEcCtD
Lomitapide—Increased appetite—Epirubicin—thyroid cancer	0.00138	0.0023	CcSEcCtD
Lomitapide—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.00138	0.00229	CcSEcCtD
Lomitapide—Body temperature increased—Sorafenib—thyroid cancer	0.00136	0.00227	CcSEcCtD
Lomitapide—Abdominal pain—Sorafenib—thyroid cancer	0.00136	0.00227	CcSEcCtD
Lomitapide—Dermatitis bullous—Epirubicin—thyroid cancer	0.00136	0.00226	CcSEcCtD
Lomitapide—Pain in extremity—Epirubicin—thyroid cancer	0.0013	0.00216	CcSEcCtD
Lomitapide—Increased appetite—Doxorubicin—thyroid cancer	0.00128	0.00212	CcSEcCtD
Lomitapide—Migraine—Epirubicin—thyroid cancer	0.00128	0.00212	CcSEcCtD
Lomitapide—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00126	0.00209	CcSEcCtD
Lomitapide—Asthenia—Sorafenib—thyroid cancer	0.00124	0.00206	CcSEcCtD
Lomitapide—Dehydration—Epirubicin—thyroid cancer	0.00121	0.00201	CcSEcCtD
Lomitapide—Pain in extremity—Doxorubicin—thyroid cancer	0.0012	0.002	CcSEcCtD
Lomitapide—Liver function test abnormal—Epirubicin—thyroid cancer	0.0012	0.00199	CcSEcCtD
Lomitapide—Dry skin—Epirubicin—thyroid cancer	0.00119	0.00198	CcSEcCtD
Lomitapide—Abdominal pain upper—Epirubicin—thyroid cancer	0.00118	0.00197	CcSEcCtD
Lomitapide—Migraine—Doxorubicin—thyroid cancer	0.00118	0.00196	CcSEcCtD
Lomitapide—Diarrhoea—Sorafenib—thyroid cancer	0.00118	0.00196	CcSEcCtD
Lomitapide—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00117	0.00194	CcSEcCtD
Lomitapide—Nasopharyngitis—Epirubicin—thyroid cancer	0.00116	0.00193	CcSEcCtD
Lomitapide—Gastritis—Epirubicin—thyroid cancer	0.00115	0.00191	CcSEcCtD
Lomitapide—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00114	0.0019	CcSEcCtD
Lomitapide—Dizziness—Sorafenib—thyroid cancer	0.00114	0.0019	CcSEcCtD
Lomitapide—Abdominal distension—Epirubicin—thyroid cancer	0.00113	0.00188	CcSEcCtD
Lomitapide—Influenza—Epirubicin—thyroid cancer	0.00112	0.00186	CcSEcCtD
Lomitapide—Dehydration—Doxorubicin—thyroid cancer	0.00112	0.00186	CcSEcCtD
Lomitapide—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00111	0.00184	CcSEcCtD
Lomitapide—Dry skin—Doxorubicin—thyroid cancer	0.0011	0.00183	CcSEcCtD
Lomitapide—Vomiting—Sorafenib—thyroid cancer	0.0011	0.00182	CcSEcCtD
Lomitapide—Abdominal pain upper—Doxorubicin—thyroid cancer	0.0011	0.00182	CcSEcCtD
Lomitapide—Angina pectoris—Epirubicin—thyroid cancer	0.00109	0.00182	CcSEcCtD
Lomitapide—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00108	0.0018	CcSEcCtD
Lomitapide—Headache—Sorafenib—thyroid cancer	0.00108	0.0018	CcSEcCtD
Lomitapide—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00107	0.00178	CcSEcCtD
Lomitapide—Gastritis—Doxorubicin—thyroid cancer	0.00106	0.00177	CcSEcCtD
Lomitapide—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00106	0.00176	CcSEcCtD
Lomitapide—Abdominal distension—Doxorubicin—thyroid cancer	0.00104	0.00174	CcSEcCtD
Lomitapide—Influenza—Doxorubicin—thyroid cancer	0.00104	0.00173	CcSEcCtD
Lomitapide—Nausea—Sorafenib—thyroid cancer	0.00102	0.0017	CcSEcCtD
Lomitapide—Weight decreased—Epirubicin—thyroid cancer	0.00101	0.00169	CcSEcCtD
Lomitapide—Angina pectoris—Doxorubicin—thyroid cancer	0.00101	0.00168	CcSEcCtD
Lomitapide—Infestation—Epirubicin—thyroid cancer	0.000999	0.00166	CcSEcCtD
Lomitapide—Infestation NOS—Epirubicin—thyroid cancer	0.000999	0.00166	CcSEcCtD
Lomitapide—Haematuria—Epirubicin—thyroid cancer	0.000953	0.00159	CcSEcCtD
Lomitapide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000945	0.00157	CcSEcCtD
Lomitapide—Weight decreased—Doxorubicin—thyroid cancer	0.000938	0.00156	CcSEcCtD
Lomitapide—Sinusitis—Epirubicin—thyroid cancer	0.000938	0.00156	CcSEcCtD
Lomitapide—Infestation NOS—Doxorubicin—thyroid cancer	0.000925	0.00154	CcSEcCtD
Lomitapide—Infestation—Doxorubicin—thyroid cancer	0.000925	0.00154	CcSEcCtD
Lomitapide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000886	0.00147	CcSEcCtD
Lomitapide—Haematuria—Doxorubicin—thyroid cancer	0.000882	0.00147	CcSEcCtD
Lomitapide—Connective tissue disorder—Epirubicin—thyroid cancer	0.000882	0.00147	CcSEcCtD
Lomitapide—Urethral disorder—Epirubicin—thyroid cancer	0.000879	0.00146	CcSEcCtD
Lomitapide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000874	0.00145	CcSEcCtD
Lomitapide—Sinusitis—Doxorubicin—thyroid cancer	0.000867	0.00144	CcSEcCtD
Lomitapide—Eye disorder—Epirubicin—thyroid cancer	0.000838	0.00139	CcSEcCtD
Lomitapide—Cardiac disorder—Epirubicin—thyroid cancer	0.000833	0.00139	CcSEcCtD
Lomitapide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00082	0.00136	CcSEcCtD
Lomitapide—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000816	0.00136	CcSEcCtD
Lomitapide—Urethral disorder—Doxorubicin—thyroid cancer	0.000814	0.00135	CcSEcCtD
Lomitapide—Mediastinal disorder—Epirubicin—thyroid cancer	0.000808	0.00134	CcSEcCtD
Lomitapide—Chills—Epirubicin—thyroid cancer	0.000805	0.00134	CcSEcCtD
Lomitapide—Malnutrition—Epirubicin—thyroid cancer	0.000781	0.0013	CcSEcCtD
Lomitapide—Eye disorder—Doxorubicin—thyroid cancer	0.000776	0.00129	CcSEcCtD
Lomitapide—Cardiac disorder—Doxorubicin—thyroid cancer	0.00077	0.00128	CcSEcCtD
Lomitapide—Flatulence—Epirubicin—thyroid cancer	0.00077	0.00128	CcSEcCtD
Lomitapide—Back pain—Epirubicin—thyroid cancer	0.000755	0.00126	CcSEcCtD
Lomitapide—Muscle spasms—Epirubicin—thyroid cancer	0.000751	0.00125	CcSEcCtD
Lomitapide—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000748	0.00124	CcSEcCtD
Lomitapide—Chills—Doxorubicin—thyroid cancer	0.000745	0.00124	CcSEcCtD
Lomitapide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000725	0.00121	CcSEcCtD
Lomitapide—Malnutrition—Doxorubicin—thyroid cancer	0.000723	0.0012	CcSEcCtD
Lomitapide—Anaemia—Epirubicin—thyroid cancer	0.000722	0.0012	CcSEcCtD
Lomitapide—Flatulence—Doxorubicin—thyroid cancer	0.000712	0.00118	CcSEcCtD
Lomitapide—Malaise—Epirubicin—thyroid cancer	0.000704	0.00117	CcSEcCtD
Lomitapide—Vertigo—Epirubicin—thyroid cancer	0.000702	0.00117	CcSEcCtD
Lomitapide—Back pain—Doxorubicin—thyroid cancer	0.000699	0.00116	CcSEcCtD
Lomitapide—Muscle spasms—Doxorubicin—thyroid cancer	0.000695	0.00116	CcSEcCtD
Lomitapide—Palpitations—Epirubicin—thyroid cancer	0.00069	0.00115	CcSEcCtD
Lomitapide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00067	0.00112	CcSEcCtD
Lomitapide—Anaemia—Doxorubicin—thyroid cancer	0.000668	0.00111	CcSEcCtD
Lomitapide—Chest pain—Epirubicin—thyroid cancer	0.000665	0.00111	CcSEcCtD
Lomitapide—Myalgia—Epirubicin—thyroid cancer	0.000665	0.00111	CcSEcCtD
Lomitapide—Arthralgia—Epirubicin—thyroid cancer	0.000665	0.00111	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00066	0.0011	CcSEcCtD
Lomitapide—Discomfort—Epirubicin—thyroid cancer	0.000657	0.00109	CcSEcCtD
Lomitapide—Malaise—Doxorubicin—thyroid cancer	0.000652	0.00108	CcSEcCtD
Lomitapide—Dry mouth—Epirubicin—thyroid cancer	0.00065	0.00108	CcSEcCtD
Lomitapide—Vertigo—Doxorubicin—thyroid cancer	0.000649	0.00108	CcSEcCtD
Lomitapide—Palpitations—Doxorubicin—thyroid cancer	0.000639	0.00106	CcSEcCtD
Lomitapide—Infection—Epirubicin—thyroid cancer	0.000633	0.00105	CcSEcCtD
Lomitapide—Nervous system disorder—Epirubicin—thyroid cancer	0.000625	0.00104	CcSEcCtD
Lomitapide—Skin disorder—Epirubicin—thyroid cancer	0.000619	0.00103	CcSEcCtD
Lomitapide—Hyperhidrosis—Epirubicin—thyroid cancer	0.000616	0.00102	CcSEcCtD
Lomitapide—Myalgia—Doxorubicin—thyroid cancer	0.000615	0.00102	CcSEcCtD
Lomitapide—Arthralgia—Doxorubicin—thyroid cancer	0.000615	0.00102	CcSEcCtD
Lomitapide—Chest pain—Doxorubicin—thyroid cancer	0.000615	0.00102	CcSEcCtD
Lomitapide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000611	0.00102	CcSEcCtD
Lomitapide—Discomfort—Doxorubicin—thyroid cancer	0.000608	0.00101	CcSEcCtD
Lomitapide—Dry mouth—Doxorubicin—thyroid cancer	0.000602	0.001	CcSEcCtD
Lomitapide—Infection—Doxorubicin—thyroid cancer	0.000586	0.000975	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000581	0.000966	CcSEcCtD
Lomitapide—Nervous system disorder—Doxorubicin—thyroid cancer	0.000578	0.000962	CcSEcCtD
Lomitapide—Skin disorder—Doxorubicin—thyroid cancer	0.000573	0.000953	CcSEcCtD
Lomitapide—Paraesthesia—Epirubicin—thyroid cancer	0.000572	0.000952	CcSEcCtD
Lomitapide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00057	0.000948	CcSEcCtD
Lomitapide—Somnolence—Epirubicin—thyroid cancer	0.000567	0.000943	CcSEcCtD
Lomitapide—Dyspepsia—Epirubicin—thyroid cancer	0.000561	0.000933	CcSEcCtD
Lomitapide—Decreased appetite—Epirubicin—thyroid cancer	0.000554	0.000922	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00055	0.000915	CcSEcCtD
Lomitapide—Fatigue—Epirubicin—thyroid cancer	0.000549	0.000914	CcSEcCtD
Lomitapide—Constipation—Epirubicin—thyroid cancer	0.000545	0.000907	CcSEcCtD
Lomitapide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000537	0.000894	CcSEcCtD
Lomitapide—Paraesthesia—Doxorubicin—thyroid cancer	0.00053	0.000881	CcSEcCtD
Lomitapide—Feeling abnormal—Epirubicin—thyroid cancer	0.000525	0.000874	CcSEcCtD
Lomitapide—Somnolence—Doxorubicin—thyroid cancer	0.000524	0.000872	CcSEcCtD
Lomitapide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000521	0.000867	CcSEcCtD
Lomitapide—Dyspepsia—Doxorubicin—thyroid cancer	0.000519	0.000864	CcSEcCtD
Lomitapide—Decreased appetite—Doxorubicin—thyroid cancer	0.000513	0.000853	CcSEcCtD
Lomitapide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000509	0.000847	CcSEcCtD
Lomitapide—Fatigue—Doxorubicin—thyroid cancer	0.000508	0.000846	CcSEcCtD
Lomitapide—Constipation—Doxorubicin—thyroid cancer	0.000504	0.000839	CcSEcCtD
Lomitapide—Abdominal pain—Epirubicin—thyroid cancer	0.000504	0.000838	CcSEcCtD
Lomitapide—Body temperature increased—Epirubicin—thyroid cancer	0.000504	0.000838	CcSEcCtD
Lomitapide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000486	0.000808	CcSEcCtD
Lomitapide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000482	0.000802	CcSEcCtD
Lomitapide—Abdominal pain—Doxorubicin—thyroid cancer	0.000466	0.000776	CcSEcCtD
Lomitapide—Body temperature increased—Doxorubicin—thyroid cancer	0.000466	0.000776	CcSEcCtD
Lomitapide—Asthenia—Epirubicin—thyroid cancer	0.000457	0.000761	CcSEcCtD
Lomitapide—Diarrhoea—Epirubicin—thyroid cancer	0.000436	0.000725	CcSEcCtD
Lomitapide—Asthenia—Doxorubicin—thyroid cancer	0.000423	0.000704	CcSEcCtD
Lomitapide—Dizziness—Epirubicin—thyroid cancer	0.000421	0.000701	CcSEcCtD
Lomitapide—Vomiting—Epirubicin—thyroid cancer	0.000405	0.000674	CcSEcCtD
Lomitapide—Diarrhoea—Doxorubicin—thyroid cancer	0.000403	0.000671	CcSEcCtD
Lomitapide—Headache—Epirubicin—thyroid cancer	0.000399	0.000664	CcSEcCtD
Lomitapide—Dizziness—Doxorubicin—thyroid cancer	0.00039	0.000649	CcSEcCtD
Lomitapide—Nausea—Epirubicin—thyroid cancer	0.000379	0.00063	CcSEcCtD
Lomitapide—Vomiting—Doxorubicin—thyroid cancer	0.000375	0.000624	CcSEcCtD
Lomitapide—Headache—Doxorubicin—thyroid cancer	0.000369	0.000615	CcSEcCtD
Lomitapide—Nausea—Doxorubicin—thyroid cancer	0.00035	0.000583	CcSEcCtD
